Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system

References

• Global Advisory Committee on Vaccine Safety. 6-7 December 2017. Releve epidemiologique hebdomadaire / Section d’hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations . 2018;93:17–30.
   PubMedGoogle Scholar
• Tomianovic D, Bauwens J, Heininger U, Bonhoeffer J. Global vaccine safety assessment: challenges and opportunities. Pediatr Infect Dis J. 2016;35:446–48. doi:10.1097/INF.0000000000000983.
   PubMed Web of Science ®Google Scholar
• Yoon D, Kim JH, Lee H, Shin JY. Updates on vaccine safety and post-licensure surveillance for adverse events following immunization in South Korea, 2005-2017. Yonsei Med J. 2020;61:623–30. doi:10.3349/ymj.2020.61.7.623.
   PubMed Web of Science ®Google Scholar
• Oliveira PMN, Lignani LK, Conceicao DAD, Farias P, Takey PRG, Maia MLS, Camacho LAB. Surveillance of adverse events following immunization in the late 2010s: an overview of the importance, tools, and challenges. Cad Saude Publica. 2020;36(Suppl 2):e00182019. doi:10.1590/0102-311x00182019.
   Google Scholar
• Sato APS, Ferreira VLR, Tauil MC, Rodrigues LC, Barros MB, Martineli E, Costa ÂA, Inenami M, Waldman EA. Use of electronic immunization registry in the surveillance of adverse events following immunization. Rev Saude Publica. 2018;52:4. doi:10.11606/S1518-8787.2018052000295.
   PubMed Web of Science ®Google Scholar
• Dey A, Wang H, Quinn H, Pillsbury A, Glover C, Hickie M, Wood N, Beard F, Macartney K. Surveillance of adverse events following immunisation in Australia: annual report, 2018. Commun Dis Intell. 2018;2020:44.
   Google Scholar
• Ranganath BG, Hiremath SG. Adverse events following immunisation with SA 14-14-2 Japanese encephalitis vaccine in children of Kolar in Karnataka. J Indian Med Assoc. 2012;110:10–12.
   PubMedGoogle Scholar
• Lawrence G, Campbell-Lloyd S, Rixon G. Monitoring adverse events following immunisation. N S W Public Health Bull. 2003;14:21–24. doi:10.1071/NB03006.
   PubMedGoogle Scholar
• Al Awaidy S, Bawikar S, Prakash KR, Al Rawahi B, Mohammed AJ. Surveillance of adverse events following immunization: 10 years’ experience in Oman. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2010;16:474–80.
   PubMedGoogle Scholar
• Yih WK, Lee GM, Lieu TA, Ball R, Kulldorff M, Rett M, Wahl PM, McMahill-Walraven CN, Platt R, Salmon DA, et al. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. Am J Epidemiol. 2012;175:1120–28. doi:10.1093/aje/kws197.
   PubMed Web of Science ®Google Scholar
• Liu D, Wu W, Li K, Xu D, Ye J, Li L, Wang H. Surveillance of adverse events following immunization in China: past, present, and future. Vaccine. 2015;33:4041–46. doi:10.1016/j.vaccine.2015.04.060.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li Q, Lin L, Chen E, Chen Y, Qi X. Surveillance for adverse events following immunization from 2008 to 2011 in Zhejiang Province, China. Clin vacc immunol. 2013;20:211–17. doi:10.1128/CVI.00541-12.
   PubMedGoogle Scholar
• Choe YJ, Cho H, Song KM, Kim JH, Han OP, Kwon YH, Bae GR, Lee HJ, Lee J-K. Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea. Jpn J Infect Dis. 2011;64:297–303.
   PubMed Web of Science ®Google Scholar
• Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33:4398–405. doi:10.1016/j.vaccine.2015.07.035.
   PubMed Web of Science ®Google Scholar
• Mahajan D, Roomiani I, Gold MS, Lawrence GL, McIntyre PB, Menzies RI. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Commun Dis Intell Q Rep. 2010;34:259–76.
   PubMedGoogle Scholar
• Niu MT, Ball R, Woo EJ, Burwen DR, Knippen M, Braun MM, VAERS Working Group Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007. Vaccine. 2009;27:290–97. doi:10.1016/j.vaccine.2008.10.044.
   PubMed Web of Science ®Google Scholar
• Nzolo D, Ntetani Aloni M, Mpiempie Ngamasata T, Mvete Luemba B, Bazundama Marfeza S, Bothale Ekila M, Nsibu CN, Tona NL. Adverse events following immunization with oral poliovirus in Kinshasa, Democratic Republic of Congo: preliminary results. Pathog Glob Health. 2013;107:381–84. doi:10.1179/2047773213Y.0000000113.
   PubMed Web of Science ®Google Scholar
• Silva SS, Oliveira VC, Ribeiro HC, Alves TG, Cavalcante RB, Guimaraes EA. Analysis of adverse events following immunization in Minas Gerais, Brazil, 2011: a cross-sectional study. Epidemiologia e servicos de saude. 2016;25:45–54. doi:10.5123/S1679-49742016000100005.
   PubMed Web of Science ®Google Scholar
• Clothier HJ, Lawrie J, Lewis G, Russell M, Crawford NW, Buttery JP. SAEFVIC: surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018. Commun Dis Intell. 2018;2020:44.
   Google Scholar
• Mentzer D, Oberle D, Keller-Stanislawski B. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016. Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin. 2018;23. doi:10.2807/1560-7917.ES.2018.23.17.17-00468.
   Google Scholar
• Samuels S, Marijne Heeren A, Zijlmans H, Welters MJP, Van Den Berg JH, Philips D, Kvistborg P, Ehsan I, Scholl SME, Nuijen B, et al. HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia. Cancer Immunol Immunother. 2017;66:1163–73. doi:10.1007/s00262-017-2006-y.
   PubMed Web of Science ®Google Scholar
• Wu WD, Liu DW, Wu BB. [Analysis on the surveillance of adverse events following immunization in China, 2007-2008]. Zhongguo Yi Miao He Mian Yi. 2009;15:538.
   PubMedGoogle Scholar
• Yu L, Lu D, Yang H, Zou J, Wang H, Zheng M, Hu J. A comparative and correlative study of the Voice-Related Quality of Life (V-RQOL) and the Voice Activity and Participation Profile (VAPP) for voice-related quality of life among teachers with and without voice disorders. Medicine. 2019;98:e14491. doi:10.1097/MD.0000000000014491.
   PubMed Web of Science ®Google Scholar
• Bermudez-de-Alvear RM, Galvez-Ruiz P, Martinez-Arquero AG, Rando-Marquez S, Fernandez-Contreras E. Evaluation of psychometric properties of voice activity and participation profile (VAPP): a Spanish version. J Voice. 2019;33:582 e15- e22. doi:10.1016/j.jvoice.2018.01.005.
   PubMed Web of Science ®Google Scholar
• Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenza like illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009;169:382–88. doi:10.1093/aje/kwn310.
   PubMed Web of Science ®Google Scholar
• Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet. 2009;374:2115–22. doi:10.1016/S0140-6736(09)61877-8.
   PubMed Web of Science ®Google Scholar
• Hauck LJ, White C, Feasby TE, Zochodne DW, Svenson LW, Hill MD. Incidence of Guillain-Barre syndrome in Alberta, Canada: an administrative data study. J Neurol Neurosurg Psychiatry. 2008;79:318–20. doi:10.1136/jnnp.2007.118810.
   PubMed Web of Science ®Google Scholar
• Chakravarty A. Neurologic illness following post-exposure prophylaxis with purified chick embryo cell antirabies vaccine. J Assoc Physicians India. 2001;49:927–28.
   PubMedGoogle Scholar